P
Paul J. Newey
Researcher at University of Dundee
Publications - 34
Citations - 1870
Paul J. Newey is an academic researcher from University of Dundee. The author has contributed to research in topics: Multiple endocrine neoplasia & Population. The author has an hindex of 13, co-authored 26 publications receiving 1510 citations. Previous affiliations of Paul J. Newey include University of Oxford.
Papers
More filters
Journal ArticleDOI
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)
Rajesh V. Thakker,Paul J. Newey,Gerard V Walls,John P. Bilezikian,Henning Dralle,Peter R. Ebeling,Shlomo Melmed,Akihiro Sakurai,Francesco Tonelli,Maria Luisa Brandi +9 more
TL;DR: It is recommended that MEN1 patients and their families should be cared for by multidisciplinary teams comprising relevant specialists with experience in the diagnosis and treatment of patients with endocrine tumors.
Journal ArticleDOI
Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism‐jaw tumor syndrome (HPT‐JT) and parathyroid tumors
TL;DR: Heterozygous germline CDC73 mutations are detected in the majority of patients with HPT‐JT, and the demonstration of loss of heterozygosity (LOH) at the CDC73 locus in tumors from affected individuals is consistent with a tumor suppressor role.
Journal ArticleDOI
Asymptomatic Children with Multiple Endocrine Neoplasia Type 1 Mutations May Harbor Nonfunctioning Pancreatic Neuroendocrine Tumors
Paul J. Newey,Jeshmi Jeyabalan,Gerard V Walls,Paul T. Christie,Fergus V. Gleeson,Steve Gould,Paul R. V. Johnson,Rachel R. Phillips,Fiona Ryan,Brian Shine,Michael R. Bowl,Rajesh V. Thakker +11 more
TL;DR: Nonfunctioning pancreatic neuroendocrine tumors may occur in asymptomatic children with MEN1 mutations, and screening for such enteropancreatic tumors in MEN1 children should be considered earlier than the age of 20 yr, as is currently recommended by the international guidelines.
Journal ArticleDOI
Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1
TL;DR: The early detection of P-NETs by circulating biomarkers and imaging modalities, and their appropriate treatments by surgical approaches and/or radionuclide therapy, chemotherapy, and biotherapy pose challenges and controversies are reviewed.
Journal ArticleDOI
Whole-exome sequencing studies of nonfunctioning pituitary adenomas.
Paul J. Newey,M. Andrew Nesbit,Andrew J. Rimmer,Rosie A. Head,Caroline M Gorvin,Moustafa Attar,Lorna Gregory,John A.H. Wass,David Buck,Niki Karavitaki,Ashley B. Grossman,Gilean McVean,Olaf Ansorge,Rajesh V. Thakker +13 more
TL;DR: Pituitary NFAs harbor few somatic mutations consistent with their low proliferation rates and benign nature, but mechanisms other than somatic mutation are likely involved in the etiology of sporadic pituitaryNFAs.